TY - JOUR
T1 - Disease patterns in late-onset ulcerative colitis
T2 - Results from the IG-IBD “AGED study”
AU - Fries, Walter
AU - Viola, Anna Maria
AU - Manetti, Natalia
AU - Frankovic, Iris
AU - Pugliese, Daniela
AU - Monterubbianesi, Rita
AU - Scalisi, Giuseppe
AU - Aratari, Annalisa
AU - Cantoro, Laura
AU - Cappello, Maria
AU - Samperi, Leonardo
AU - Saibeni, Simone
AU - Casella, Giovanni
AU - Mocci, Giammarco
AU - Rea, Matilde
AU - Furfaro, Federica
AU - Contaldo, Antonella
AU - Magarotto, Andrea
AU - Calella, Francesca
AU - Manguso, Francesco
AU - Inserra, Gaetano
AU - Privitera, Antonino C.
AU - Principi, Mariabeatrice
AU - Castiglione, Fabiana
AU - Caprioli, Flavio
AU - Ardizzone, Sandro
AU - Danese, Silvio
AU - Papi, Claudio
AU - Bossa, Fabrizio
AU - Kohn, Anna
AU - Armuzzi, Alessandro
AU - D'Incà, Renata
AU - Annese, Vito
AU - Alibrandi, Angela
AU - Bonovas, Stefanos
AU - Fiorino, Gionata
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Background Late-onset UC represents an important issue for the near future, but its outcomes and relative therapeutic strategies are yet poorly studied. Aim To better define the natural history of late-onset ulcerative colitis. Methods In a multicenter retrospective study, we investigated the disease presentation and course in the first 3 years in 1091 UC patients divided into 3 age-groups: diagnosis ≥65 years, 40–64 years, and <40 years. Disease patterns, medical and surgical therapies, and risk factors for disease outcomes were analyzed. Results Chronic active or relapsing disease accounts for 44% of patients with late-onset UC. Across all age-groups, these disease patterns require 3–6 times more steroids than remitting disease, but immunomodulators and, to a lesser extent, biologics are less frequently prescribed in the elderly. Advanced age, concomitant diseases and related therapies were found to be inversely associated with the use of immunomodulators or biologics, but not with surgery. Conclusions The conclusion that late-onset UC follows a mild course may apply only to a subset of patients. an important percentage of elderly patients present with more aggressive disease. Since steroid use and surgery rates did not differ in this subgroup, lower use of immunosuppressive therapy and biologics may reflect concerns in prescribing these therapies in the elderly.
AB - Background Late-onset UC represents an important issue for the near future, but its outcomes and relative therapeutic strategies are yet poorly studied. Aim To better define the natural history of late-onset ulcerative colitis. Methods In a multicenter retrospective study, we investigated the disease presentation and course in the first 3 years in 1091 UC patients divided into 3 age-groups: diagnosis ≥65 years, 40–64 years, and <40 years. Disease patterns, medical and surgical therapies, and risk factors for disease outcomes were analyzed. Results Chronic active or relapsing disease accounts for 44% of patients with late-onset UC. Across all age-groups, these disease patterns require 3–6 times more steroids than remitting disease, but immunomodulators and, to a lesser extent, biologics are less frequently prescribed in the elderly. Advanced age, concomitant diseases and related therapies were found to be inversely associated with the use of immunomodulators or biologics, but not with surgery. Conclusions The conclusion that late-onset UC follows a mild course may apply only to a subset of patients. an important percentage of elderly patients present with more aggressive disease. Since steroid use and surgery rates did not differ in this subgroup, lower use of immunosuppressive therapy and biologics may reflect concerns in prescribing these therapies in the elderly.
KW - Outcome
KW - Steroids
KW - Surgery
KW - Thiopurines
KW - Tumors
UR - http://www.scopus.com/inward/record.url?scp=85000925928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85000925928&partnerID=8YFLogxK
U2 - 10.1016/j.dld.2016.09.006
DO - 10.1016/j.dld.2016.09.006
M3 - Article
AN - SCOPUS:85000925928
VL - 49
SP - 17
EP - 23
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
SN - 1590-8658
IS - 1
ER -